A Clinical Study to Evaluate the Efficacy and Safety of Bempedoic Acid

Inclusion criteria

• 18 years and older. 2. 18.5 kg/m2 ≤Body Mass Index (BMI) ≤35 kg/m2. 3. Diagnosis with ASCVD or have high-risk ASCVD, and/or diagnosis with HeFH.4.Be on stable lipid-modifying therapy for at least 4 weeks prior to screening, including moderate to high-dose statins with or without other lipid-modifying therapy (cholesterol absorption inhibitors[ezetimibe, Hyzetimibe]，fibrates [except gemfibrozil]）; 5.Fasting LDL-C must meet any one of the following

• For participants with high risk of ASCVD: LDL-C ≥ 2.6 mmol/L (or 100 mg/dL);
• For participants with extremely high risk of ASCVD: LDL-C≥ 1.8 mmol/L (or 70 mg/dL); 3) For participants with ultra-high risk of ASCVD: LDL-C≥ 1.4 mmol/L (or 55 mg/dL).

6.Fully understand the purpose and requirements of the study, voluntarily participate in the clinical trial, and sign a written informed consent form.

Exclusion criteria

• Known allergy to any component of the investigational drug or its excipients or related preparations, or a history of allergic diseases (e.g., asthma, urticaria, eczema) or allergic constitution.
• Diagnosis with HoFH.
• History of tendon diseases or tendon ruptures before the screening.
• Severe, uncontrolled concomitant conditions that may affect drug absorption or have a significant impact on lipid level.
• Hyperthyroidism or uncontrolled hypothyroidism
• Uncontrolled hypertension
• Severe cardiovascular or cerebrovascular events in the past 3 months
• History of nephrotic syndrome or glomerulonephritis or severe renal dysfunction.
• Liver disease or dysfunction